Partner Jeff Fessler Joins Client ContraVir Pharmaceuticals, Inc. at NASDAQ Opening Bell Ringing
Press Release – New York, NY – March 22, 2016 – Sichenzia Ross Friedman Ference LLP partner Jeff Fessler joined representatives of client ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, at the NASDAQ MarketSite in Times Square to ring the March 21 closing bell.
ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. The company’s common stock has traded on The Nasdaq Capital Market under the symbol “CTRV” since February 27, 2015.
- Sichenzia Ross Ference LLP Represents A.G.P./ Alliance Global Partners as Placement Agent in $15M Registered Direct Offering of Arcimoto, Inc. - November 24, 2020
- Founding Partner Marc J. Ross, Esq. Quoted Regarding Cannabis SPACs Post U.S. Presidential Elections - November 23, 2020
- 2020 Income Tax Rates and Deductions - November 19, 2020